Walgreens Expands Specialty Pharmacy Network to Address Increasing Need for Complex Treatments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 19 2025
0mins
Should l Buy GILD?
Source: Benzinga
Walgreens Specialty Pharmacy Expansion: Walgreens Boots Alliance announced a significant expansion of its specialty pharmacy network, increasing its limited distribution drug (LDD) portfolio to 265 therapies.
Independent Operations: Unlike pharmacies tied to pharmacy benefit managers, Walgreens Specialty Pharmacy operates independently, allowing for flexible collaborations with insurers and healthcare providers.
Support for Complex Treatments: The company employs a nationwide team of healthcare professionals dedicated to assisting patients with unique conditions and complex treatment needs, reflecting the growth in the specialty medicine sector.
Stock Performance: WBA shares have seen a gain of over 10% in the past year, with current trading at $12.03, indicating positive investor sentiment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 132.690
Low
105.00
Averages
137.88
High
154.00
Current: 132.690
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Yeztugo Injection Faces Insurance Hurdles Despite Initial Uptake
- Market Acceptance: Since its June launch, Yeztugo has seen usage climb to nearly 75 patients, significantly lower than the expected 700 PrEP patients, indicating a lack of interest among patients that hampers Gilead's market expansion strategy.
- Insurance Coverage Issues: While Gilead claims over 90% of insurers cover Yeztugo, many patients face injection costs exceeding $14,000 and insurance denials, leading them to opt for cheaper daily medications, which impacts sales growth.
- Prescription Data Comparison: In the first quarter, over 9,000 prescriptions were written for Yeztugo, compared to 461,000 for Descovy, highlighting a preference for traditional daily medications that limits Yeztugo's market share.
- Future Sales Expectations: Analysts estimate that Yeztugo's annual sales could exceed $5 billion by 2032, although current insurance coverage and patient acceptance issues may hinder the achievement of this target.
See More
Analysis of Upcoming U.S. Jobs Report Outlook
- Job Market Expectations: According to FactSet consensus estimates, the U.S. is expected to add only 50,000 jobs in April, significantly lower than March's 178,000, indicating signs of economic slowdown that could impact investor confidence.
- Unemployment Rate Stability: The unemployment rate is anticipated to remain steady at 4.3%, suggesting that despite the decrease in job additions, the labor market remains relatively stable, potentially alleviating fears of an economic downturn.
- GDP Growth Situation: The U.S. GDP grew at a seasonally adjusted annualized rate of 2% in the first quarter, higher than the fourth quarter's 0.5% but below the 2.2% estimate, reflecting economic sluggishness that may influence future monetary policy decisions.
- Market Volatility: Despite a strong performance in April, with the S&P 500 and Nasdaq hitting record highs, investors should remain cautious of the upcoming
See More
S&P 500 Hits Record Highs, AI Stocks Shine
- S&P 500 Performance: The S&P 500 is on track to close at another record high after its best month since November 2020, indicating strong market confidence in economic recovery as of Friday.
- AI Stock Surge: AI-related stocks like Arm, Broadcom, and Alphabet saw significant gains in April, with Arm surging nearly 40% and others rising over 30%, reflecting sustained investor enthusiasm and strong demand for AI technologies.
- Impact of Rising Memory Prices: Companies like Meta and Microsoft have raised their capital expenditure guidance due to surging memory prices, with Microsoft projecting $190 billion in capex for 2026, of which $25 billion is attributed to rising component costs, highlighting the tightness in the memory market.
- Multi-Year Supply Agreements: SanDisk has signed five multi-year supply agreements valued at over $11 billion, ensuring stable demand for its customers and indicating strong bargaining power for memory manufacturers, which could impact future sales and margins.
See More
Biotech Dealmaking Accelerates Ahead of Patent Cliffs
- Surge in M&A Activity: Biotech M&A deal value reached $84 billion in Q1 2026, a staggering 89.4% increase from $44.4 billion a year earlier, indicating a robust market recovery, with projections suggesting total annual deal value could exceed $250 billion, ranking second only to 2019.
- Patent Cliffs Catalyst: Pharmaceutical companies are accelerating M&A due to impending patent cliffs, with over $300 billion in revenue facing loss of exclusivity in the next five years, particularly with Merck's Keytruda losing exclusivity in 2028, adding to market uncertainty.
- Strong Cash Reserves Fuel Acquisitions: Eli Lilly, for instance, ended 2025 with over $7.27 billion in cash and equivalents, having spent over $35 billion on acquisitions in 2023, demonstrating that strong financial positions make M&A decisions more justifiable at the board level.
- Mid-Sized Deals Dominate: Recent CEO transitions at GSK and Novo Nordisk have led to more aggressive M&A strategies, with analysts noting that the global revenue exposed to patent expirations over the next seven years is 2.5 times higher than in the last 16 years, further driving the activity in mid-sized deals.
See More
Gilead Sciences Investor Conference Schedule Announced
- Conference Schedule: Gilead Sciences has announced its participation in several investor conferences, including the BofA Securities Health Care Conference on May 12, RBC Capital Markets Global Healthcare Conference on May 19, Bernstein Annual Strategic Decisions Conference on May 28, and Goldman Sachs Annual Global Healthcare Conference on June 9, highlighting its leadership in the biopharmaceutical sector.
- Live Webcasts: All conferences will be accessible via the company's investor page, allowing investors to view live presentations and access replays for at least 30 days post-event, ensuring broad dissemination and transparency of information.
- Company Background: Gilead Sciences is a biopharmaceutical company with over three decades of breakthroughs in medicine, committed to developing innovative therapies to prevent and treat life-threatening diseases such as HIV, viral hepatitis, COVID-19, and cancer, reflecting its responsibility in global health.
- Global Operations: Operating in over 35 countries with headquarters in Foster City, California, Gilead's global reach and innovative capabilities position it as a key player in the biopharmaceutical industry, driving improvements in global health.
See More
Analysis of QQQI ETF's 52-Week Price Fluctuations
- Price Range Analysis: QQQI ETF's 52-week low is $46.5309 and high is $55.93, with the latest trade at $53.79, indicating relative stability in the ETF's market position, which may attract investor interest.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, helping them assess market trends and timing for investments.
- Unit Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units', allowing for flexibility as units can be created or destroyed based on investor demand, impacting the liquidity of underlying assets.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding highlights significant inflows (new units created) or outflows (old units destroyed), directly affecting the ETF's underlying holdings and consequently its market performance.
See More
Yeztugo Injection Faces Insurance Hurdles Despite Initial Uptake
- Market Acceptance: Since its June launch, Yeztugo has seen usage climb to nearly 75 patients, significantly lower than the expected 700 PrEP patients, indicating a lack of interest among patients that hampers Gilead's market expansion strategy.
- Insurance Coverage Issues: While Gilead claims over 90% of insurers cover Yeztugo, many patients face injection costs exceeding $14,000 and insurance denials, leading them to opt for cheaper daily medications, which impacts sales growth.
- Prescription Data Comparison: In the first quarter, over 9,000 prescriptions were written for Yeztugo, compared to 461,000 for Descovy, highlighting a preference for traditional daily medications that limits Yeztugo's market share.
- Future Sales Expectations: Analysts estimate that Yeztugo's annual sales could exceed $5 billion by 2032, although current insurance coverage and patient acceptance issues may hinder the achievement of this target.
See More
Analysis of Upcoming U.S. Jobs Report Outlook
- Job Market Expectations: According to FactSet consensus estimates, the U.S. is expected to add only 50,000 jobs in April, significantly lower than March's 178,000, indicating signs of economic slowdown that could impact investor confidence.
- Unemployment Rate Stability: The unemployment rate is anticipated to remain steady at 4.3%, suggesting that despite the decrease in job additions, the labor market remains relatively stable, potentially alleviating fears of an economic downturn.
- GDP Growth Situation: The U.S. GDP grew at a seasonally adjusted annualized rate of 2% in the first quarter, higher than the fourth quarter's 0.5% but below the 2.2% estimate, reflecting economic sluggishness that may influence future monetary policy decisions.
- Market Volatility: Despite a strong performance in April, with the S&P 500 and Nasdaq hitting record highs, investors should remain cautious of the upcoming
See More
S&P 500 Hits Record Highs, AI Stocks Shine
- S&P 500 Performance: The S&P 500 is on track to close at another record high after its best month since November 2020, indicating strong market confidence in economic recovery as of Friday.
- AI Stock Surge: AI-related stocks like Arm, Broadcom, and Alphabet saw significant gains in April, with Arm surging nearly 40% and others rising over 30%, reflecting sustained investor enthusiasm and strong demand for AI technologies.
- Impact of Rising Memory Prices: Companies like Meta and Microsoft have raised their capital expenditure guidance due to surging memory prices, with Microsoft projecting $190 billion in capex for 2026, of which $25 billion is attributed to rising component costs, highlighting the tightness in the memory market.
- Multi-Year Supply Agreements: SanDisk has signed five multi-year supply agreements valued at over $11 billion, ensuring stable demand for its customers and indicating strong bargaining power for memory manufacturers, which could impact future sales and margins.
See More
Biotech Dealmaking Accelerates Ahead of Patent Cliffs
- Surge in M&A Activity: Biotech M&A deal value reached $84 billion in Q1 2026, a staggering 89.4% increase from $44.4 billion a year earlier, indicating a robust market recovery, with projections suggesting total annual deal value could exceed $250 billion, ranking second only to 2019.
- Patent Cliffs Catalyst: Pharmaceutical companies are accelerating M&A due to impending patent cliffs, with over $300 billion in revenue facing loss of exclusivity in the next five years, particularly with Merck's Keytruda losing exclusivity in 2028, adding to market uncertainty.
- Strong Cash Reserves Fuel Acquisitions: Eli Lilly, for instance, ended 2025 with over $7.27 billion in cash and equivalents, having spent over $35 billion on acquisitions in 2023, demonstrating that strong financial positions make M&A decisions more justifiable at the board level.
- Mid-Sized Deals Dominate: Recent CEO transitions at GSK and Novo Nordisk have led to more aggressive M&A strategies, with analysts noting that the global revenue exposed to patent expirations over the next seven years is 2.5 times higher than in the last 16 years, further driving the activity in mid-sized deals.
See More
Gilead Sciences Investor Conference Schedule Announced
- Conference Schedule: Gilead Sciences has announced its participation in several investor conferences, including the BofA Securities Health Care Conference on May 12, RBC Capital Markets Global Healthcare Conference on May 19, Bernstein Annual Strategic Decisions Conference on May 28, and Goldman Sachs Annual Global Healthcare Conference on June 9, highlighting its leadership in the biopharmaceutical sector.
- Live Webcasts: All conferences will be accessible via the company's investor page, allowing investors to view live presentations and access replays for at least 30 days post-event, ensuring broad dissemination and transparency of information.
- Company Background: Gilead Sciences is a biopharmaceutical company with over three decades of breakthroughs in medicine, committed to developing innovative therapies to prevent and treat life-threatening diseases such as HIV, viral hepatitis, COVID-19, and cancer, reflecting its responsibility in global health.
- Global Operations: Operating in over 35 countries with headquarters in Foster City, California, Gilead's global reach and innovative capabilities position it as a key player in the biopharmaceutical industry, driving improvements in global health.
See More
Analysis of QQQI ETF's 52-Week Price Fluctuations
- Price Range Analysis: QQQI ETF's 52-week low is $46.5309 and high is $55.93, with the latest trade at $53.79, indicating relative stability in the ETF's market position, which may attract investor interest.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, helping them assess market trends and timing for investments.
- Unit Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units', allowing for flexibility as units can be created or destroyed based on investor demand, impacting the liquidity of underlying assets.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding highlights significant inflows (new units created) or outflows (old units destroyed), directly affecting the ETF's underlying holdings and consequently its market performance.
See More
